All In Biotech

Drug Trial Radar · NCT05681299

Effects of GH and Lirglutide on AgRP

Effects of Administration of Growth Hormone, Without and With Liraglutide, on AgRP, Energy and Glucose Metabolism in Healthy and GH Deficient Humans

Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

May 1, 2023

Primary completion

Apr 30, 2028

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Columbia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. Testing before, during and at the completion of each arm will include blood sampling and assessments of insulin resistance, energy expenditure and body composition.

Conditions

  • Healthy
  • Growth Hormone Deficiency

Interventions

  • growth hormone and lirglutideDrug

    GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.

  • growth hormoneDrug

    GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.

  • liraglutideDrug

    Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.

  • PlaceboDrug

    Placebo will be taken by nightly subcutaneous injection at 9-11 pm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AgRP change in GH vs. placebo armsTime frame: Baseline to weeks 1, 2, 3 of each study arm.
  2. AgRP change in GH vs. GH + liraglutide armsTime frame: Baseline to weeks 1, 2, 3 of each study arm.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.